Shopping Cart
- Remove All
- Your shopping cart is currently empty
Semustine, a DNA alkylating agent, is a cancer chemotherapy compound that is nephrotoxic in patients with malignant melanoma receiving adjuvant chemotherapy for the adjuvant treatment of leukemia.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $138 | In Stock | |
5 mg | $397 | In Stock | |
10 mg | $589 | In Stock | |
25 mg | $945 | In Stock | |
50 mg | $1,280 | In Stock | |
100 mg | $1,730 | In Stock | |
500 mg | $3,460 | In Stock |
Description | Semustine, a DNA alkylating agent, is a cancer chemotherapy compound that is nephrotoxic in patients with malignant melanoma receiving adjuvant chemotherapy for the adjuvant treatment of leukemia. |
In vivo | Semustine (Me-CCNU) (150 mg×m(-2)×d(-1) once; oral; repeated every 28 days) treatment periods were within 2 - 6 months; follow-up period was 6 months. PFS at 6 months was 55.88% in the Me-CCNU group (P < 0.05). Overall survival rates at the end of the follow-up period were 97.30% in the Me-CCNU group (P > 0.05). Adverse events rates of Me-CCNU was 45.15% (P < 0.05).[2] |
Molecular Weight | 247.72 |
Formula | C10H18ClN3O2 |
Cas No. | 13909-09-6 |
Smiles | N(C(N(CCCl)N=O)=O)C1CCC(C)CC1 |
Relative Density. | 1.31 g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | Ethanol: 45.0 mg/mL (181.7 mM), Sonication is recommended. DMSO: 90.0 mg/mL (363.3 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.